Refine Search
(14)
(27)
(51)
(127)

Gastrointestinal

GlobalData provides unique and market-leading data and insights into the gastrointestinal market. Browse or search our Report Store for the latest comprehensive reports, market data, analysis and survey findings alongside industry information on key companies, markets and financial deals.

Competitor Landscape: Non-alcoholic Steatohepatitis (NASH)

  • $6,400
  • December 2018
Add to Basket Quick View Add to Saved List

Sociable Pharma’s ‘Treatment Landscape’ contains evaluations of ongoing development activities within the NASH market, analysis of current & potential future product positioning, and forecast approval dates (by quarter) for candidates in Ph...

Crohn’s Disease: Dynamic Market Forecast to 2026

  • $8,495
  • October 2018
Add to Basket Quick View Add to Saved List

Crohn’s disease is a form of inflammatory bowel disease, which is comprised of two chronic autoimmune diseases that cause intestinal inflammation: Crohn's disease and ulcerative colitis. In Crohn’s disease, chronic inflammation may affect a...

Zollinger-Ellison Syndrome (Gastrinoma) Global Clinical Trials Review, H2, 2018

  • $2,500
  • October 2018
Add to Basket Quick View Add to Saved List

GlobalData's clinical trial report, “Zollinger-Ellison Syndrome (Gastrinoma) Global Clinical Trials Review, H2, 2018" provides an overview of Zollinger-Ellison Syndrome (Gastrinoma) clinical trials scenario. This report provides top li...

Acid Indigestion (Heartburn/Pyrosis) Global Clinical Trials Review, H2, 2018

  • $2,500
  • October 2018
Add to Basket Quick View Add to Saved List

GlobalData's clinical trial report, “Acid Indigestion (Heartburn/Pyrosis) Global Clinical Trials Review, H2, 2018" provides an overview of Acid Indigestion (Heartburn/Pyrosis) clinical trials scenario. This report provides top line dat...

Acidity Global Clinical Trials Review, H2, 2018

  • $2,500
  • October 2018
Add to Basket Quick View Add to Saved List

GlobalData's clinical trial report, “Acidity Global Clinical Trials Review, H2, 2018" provides an overview of Acidity clinical trials scenario. This report provides top line data relating to the clinical trials on Acidity. Report inclu...

Alcoholic Hepatitis Global Clinical Trials Review, H2, 2018

  • $2,500
  • October 2018
Add to Basket Quick View Add to Saved List

GlobalData's clinical trial report, “Alcoholic Hepatitis Global Clinical Trials Review, H2, 2018" provides an overview of Alcoholic Hepatitis clinical trials scenario. This report provides top line data relating to the clinical trials ...

Anal Fissure Global Clinical Trials Review, H2, 2018

  • $2,500
  • October 2018
Add to Basket Quick View Add to Saved List

GlobalData's clinical trial report, “Anal Fissure Global Clinical Trials Review, H2, 2018" provides an overview of Anal Fissure clinical trials scenario. This report provides top line data relating to the clinical trials on Anal Fissur...

Anal Fistula Global Clinical Trials Review, H2, 2018

  • $2,500
  • October 2018
Add to Basket Quick View Add to Saved List

GlobalData's clinical trial report, “Anal Fistula Global Clinical Trials Review, H2, 2018" provides an overview of Anal Fistula clinical trials scenario. This report provides top line data relating to the clinical trials on Anal Fistul...

KOL Perspectives: Patient Niches in IBD

  • $2,500
  • September 2018
Add to Basket Quick View Add to Saved List

This KOL Insight briefing focuses on KOLs views of Patient Niches in IBD

Digital Landscape: Inflammatory Bowel Disease

  • $6,000
  • September 2018
Add to Basket Quick View Add to Saved List

The Digital Landscape Inflammatory Bowel Disease report analyzes digital activities undertaken by pharma in support of disease-modifying therapies for mild-to-moderate, and moderate-to-severe Crohn’s disease and ulcerative colitis (UC).

Non-Alcoholic Steatohepatitis (NASH): Dynamic Market Forecast to 2026

  • $8,495
  • September 2018
Add to Basket Quick View Add to Saved List

Non-alcoholic steatohepatitis (NASH) is a common, often clinically silent liver disease characterized by the presence of a fatty, inflamed, and damaged liver. It resembles alcoholic liver disease but occurs in people who drink little or no alco...

Competitor Landscape: Inflammatory Bowel Disease (IBD)

  • $6,400
  • September 2018
Add to Basket Quick View Add to Saved List

Sociable Pharma’s ‘Treatment Landscape’ contains evaluations of ongoing development activities within the IBD market, analysis of current & potential future product positioning, and forecast approval dates (by quarter) for candidates in Ph...

Ulcerative Colitis Global Clinical Trials Review, H2, 2018

  • $2,500
  • September 2018
Add to Basket Quick View Add to Saved List

GlobalData's clinical trial report, “Ulcerative Colitis Global Clinical Trials Review, H2, 2018" provides an overview of Ulcerative Colitis clinical trials scenario. This report provides top line data relating to the clinical trials on...

Ulcers Global Clinical Trials Review, H2, 2018

  • $2,500
  • September 2018
Add to Basket Quick View Add to Saved List

GlobalData's clinical trial report, “Ulcers Global Clinical Trials Review, H2, 2018" provides an overview of Ulcers clinical trials scenario. This report provides top line data relating to the clinical trials on Ulcers. Report includes...

KOL Perspectives: Perception of mirikizumab in moderate-to-severe UC

  • $2,500
  • August 2018
Add to Basket Quick View Add to Saved List

This KOL Insight briefing focuses on KOLs views of mirikizumab in moderate-to-severe UC